Importance Programmed cell death 1 (PD-1) inhibitor–related pneumonitis is a rare but
clinically serious and potentially life-threatening adverse event. Little is known about its …

Idiopathic pulmonary fibrosis (IPF) is a progressive, life-threatening, interstitial lung disease
of unknown etiology. The median survival of patients with IPF is only 2 to 3 years, yet some …

Idiopathic pulmonary fibrosis is a devastating, age-related lung disease of unknown cause
that has few treatment options. This disease was once thought to be a chronic inflammatory …

Fibrosing alveolitis associated with systemic sclerosis (FASSc) has a better prognosis than
idiopathic pulmonary fibrosis. In view of recent reports that idiopathic nonspecific interstitial …

Backgrounds Immune-related adverse events were reported in patients treated with immune
checkpoint inhibitors (ICIs). However, with the increasing number of immune-related …

Idiopathic pulmonary fibrosis (IPF) is a chronic fibrotic lung disease of unknown etiology.
With a gradually increasing worldwide prevalence and a mortality rate exceeding that of …

Despite the development of pharmacological therapies that are effective in slowing the
progression of idiopathic pulmonary fibrosis (IPF), it remains a debilitating and lethal …

Idiopathic interstitial pneumonias comprise usual interstitial pneumonia (UIP), nonspecific
interstitial pneumonia (NSIP), desquamative interstitial pneumonia (DIP), respiratory …

Background: Individuals with severely impaired lung function have an increased risk of lung
cancer. Whether milder reductions in forced expiratory volume in 1 second (FEV1) also …

Background: Recently, immune checkpoint inhibitors (ICIs) have been proved one of the
most promising anti-cancer therapy, series clinical trials have confirmed their efficacy. But …